Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MicroRNAs01:22

MicroRNAs

21.4K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.4K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Experimental RNAi02:15

Experimental RNAi

6.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Melatonin rhythm-mimicking smart hydrogel for circadian clock regulation and promotion of intervertebral disc regeneration.

Materials today. Bio·2026
Same author

Minipercutaneous Nephrolithotomy as an Alternative to Standard PCNL for Selected Renal Stones ≤ 2 cm: Real-World Retrospective Study.

Archivos espanoles de urologia·2026
Same author

Targeting lung cancer: synergistic therapeutic strategy of cuproptosis and immunogenic cell death.

Frontiers in cell and developmental biology·2026
Same author

Thioredoxin-interacting protein in fibrotic diseases: Mechanisms and therapeutic strategies.

The international journal of biochemistry & cell biology·2026
Same author

NTRK Fusion Landscape in 195 Positive Cases of 17 Tumors: A Chinese Multicenter Retrospective Study With Optimized Pan-TRK Immunohistochemistry (IHC) Screening.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same author

Aetiological Description of Urinary Tract Infections in Patients with Type 2 Diabetes and Construction of a Clinical Prediction Model: A Retrospective Study.

Archivos espanoles de urologia·2026

Related Experiment Video

Updated: Jul 18, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

Long Noncoding RNA MAGI2-AS3 Represses Cell Progression in Clear Cell Renal Cell Carcinoma by Modulating the

Chengquan Yan1, Pengfei Wang1, Chaofei Zhao1

  • 1Department of Urology, Area 3, Tangshan Gongren Hospital, Tangshan City, Hebei Province, 063000, China.

Critical Reviews in Eukaryotic Gene Expression
|August 21, 2023
PubMed
Summary

MAGI2-AS3, a long non-coding RNA, is decreased in clear cell renal cell carcinoma (ccRCC). It suppresses ccRCC progression by regulating miR-629-5p and PRDM16, offering a potential therapeutic target for ccRCC treatment.

More Related Videos

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

2.4K
An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.4K

Related Experiment Videos

Last Updated: Jul 18, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K
CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

2.4K
An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.4K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Clear cell renal cell carcinoma (ccRCC) is a prevalent kidney cancer subtype.
  • Understanding the molecular mechanisms underlying ccRCC progression is crucial for developing effective treatments.
  • Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in cancer development.

Purpose of the Study:

  • To elucidate the regulatory mechanism of MAGI2-AS3 in clear cell renal cell carcinoma (ccRCC).
  • To investigate the potential of MAGI2-AS3 as a therapeutic target and prognostic indicator for ccRCC.

Main Methods:

  • Analysis of expression data from The Cancer Genome Atlas (TCGA-KIRC).
  • Bioinformatic prediction of lncRNA targets (miRNA and mRNA).
  • In vitro assays (CCK-8, colony formation, Transwell migration, invasion) to assess ccRCC cell phenotypes.
  • Dual-luciferase reporter gene assays to confirm gene targeting relationships.
  • Kaplan-Meier (K-M) analysis for survival rate assessment.

Main Results:

  • MAGI2-AS3 expression is significantly decreased in ccRCC tissues and cells, correlating with tumor progression.
  • MAGI2-AS3 suppresses ccRCC cell proliferation, migration, and invasion.
  • MAGI2-AS3 directly binds to miR-629-5p, which in turn targets PRDM16.
  • MAGI2-AS3 upregulates PRDM16 by inhibiting miR-629-5p, thereby suppressing ccRCC aggressiveness.
  • High expression of MAGI2-AS3 or PRDM16 is associated with improved ccRCC patient survival.

Conclusions:

  • MAGI2-AS3 acts as a tumor suppressor in ccRCC by sponging miR-629-5p and modulating PRDM16 expression.
  • The MAGI2-AS3/miR-629-5p/PRDM16 axis represents a novel regulatory pathway in ccRCC progression.
  • This axis holds promise as a potential therapeutic target and prognostic biomarker for ccRCC.